Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.

Manuel Rubio-RivasCarlos G ForeroJosé María Mora-LujánAbelardo MonteroFrancesc FormigaNarcís A HomsJoan Albà-AlbalateLaura SánchezJordi RelloXavier Corbella

Published in: Pharmacotherapy (2021)

TCZ prevented mortality in patients hospitalized for COVID-19. This benefit was seen to a greater extent in patients receiving concomitant CS and when TCZ administration occurred within the first 10 days after symptom onset.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
ejection fraction
rheumatoid arthritis
chronic kidney disease
prognostic factors
early onset
type diabetes
peritoneal dialysis
risk factors
cardiovascular disease
coronary artery disease
respiratory syndrome coronavirus
systemic lupus erythematosus